Latest Insights - page 2 | BiopharmaTrend

Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome

Drug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can manipulate biology. …

Continue ›››

Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms

Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …

Continue ›››

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent. Everyone is talking about how Anthropic AI lab now designs drugs, hires the AlphaFold Nobel laureate, and ships Claude Science alongside Claude Code. …

Continue ›››

Seven HealthTech Trends In Europe To Watch

I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions …

Continue ›››

Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.

The System Is Buckling; Self-Care Is the Solution. Global health systems are buckling under immense pressure. When I attended the World Health Assembly in May, Dr. Wael Ali, board member …

Continue ›››

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO: several companies to watch in techbio space. …

Continue ›››

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One, a Packaged ADME Service for Early Discovery

Ginkgo Bioworks' (NYSE: DNA) Datapoints arm, Tangible Scientific, and Inductive Bio today launched ADME-One, a single-SKU service that combines a Tier 1 ADME panel, AI-driven human pharmacokinetic projection, and compound …

Continue ›››

AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.

In a recent large-scale code modernization initiative, a team used generative AI to convert a clinical data standards library from one programming language to another. Nearly 80% of the templates …

Continue ›››

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune rejuvenation.

Continue ›››

Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain

Novo Nordisk has entered a strategic partnership with OpenAI to integrate AI systems across its research, manufacturing, and commercial workflows. Initial pilot programs are expected across R&D, manufacturing, and commercial …

Continue ›››

Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic

Boston-based Life Biosciences, co-founded by David Sinclair, has closed an $80 million Series D financing to fund its first-in-human clinical program and extend operations into 2027. The capital is allocated …

Continue ›››

Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise

Jeito Capital has closed its second fund, Jeito II, at more than €1 billion, or about $1.2 billion, giving the Paris-based investor a larger pool of capital for clinical-stage biopharma …

Continue ›››